Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile

Ken Blount, PhD, Courtney Jones, BS, Bill Shannon, PhD MBA, Sharina Carter, PhD

Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile Poster image

Download this poster (327 KB)
Download the abstract (91 KB)

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA


  • Recurrent Clostridium difficile infections (rCDI) are associated with decreased taxonomic diversity in patients’ intestinal microbiome compared to healthy microbiomes.
  • RBX2660 is a standardized microbiota-based drug designed to rehabilitate a patient’s intestinal microbiome.
  • The effect of RBX2660 on rCDI patient microbiomes was evaluated by comparing pre- and post-treatment samples collected from PUNCH CD 2—a multicenter, randomized, double-blind, placebo-controlled study—to the healthy intestinal microbiome defined by the Human Microbiome Project (HMP).


  • Patients with rCDI enrolled in the PUNCH CD 2 trial were randomized to receive blinded treatment by enema of 2 doses of RBX2660 (Group A), 2 doses of placebo (Group B), or 1 dose of RBX2660 and 1 dose of placebo (Group C), with doses 7 days apart (Figure 1).
  • Success was defined as the absence of Clostridium difficile-associated diarrhea at 8 weeks following completion of the last treatment. Patients were classified as a treatment failure if all four(4) of the following criteria were met: recurrence of diarrhea less than 8 weeks after administration of the last assigned study enema, a positive laboratory diagnosis of C. difficile as conducted and reported by the study investigator, a need for retreatment for CDI, and no other cause for diarrhea.
  • Voluntary stool samples were collected from subjects at baseline and at 7, 30, and 60 days after treatment.
  • Longitudinal 16s rRNA analysis using the Illumina MiSeq platform was performed on stool samples collected from subjects in Groups A and C with successful outcomes. The variable region V4 was targeted to identify the operational taxonomic units (OTUs) in each sample.
  • Simpson and Shannon diversity values were calculated for all sample time point groups, and post-treatment diversity indices for each time point were compared to baseline using a paired Wilcoxon test. Met
  • Relative abundance data from subject samples were grouped longitudinally and compared to HMP data using a Bray-Curtis dissimilarity calculation with non-metric multi-dimensional scaling. Additional analyses were performed based on the Dirichlet-Multinomial distribution to compare group mean relative taxonomic abundances, pi, and within group over dispersion, theta.
  • Differentiation between sample communities were visualized using a Kullback-Leibler (KL) divergence analysis model (BioRankings, St. Louis, MO) KL divergence is a measure of the difference between microbial diversity at different time points or between different samples.

PUNCH CD 2 Clinical Trial Results1

  • A single dose of RBX2660 was significantly better than placebo (67%, Group C vs 46% Group B, P=0.48) (Figure 2).
  • A second dose of RBX2660 one week later (Group A) did not provide additional clinical benefit.
  • Groups A and C combined were superior to placebo (P=0.046)


  • Ninety-four (94) stool samples collected from 45 patients who received at least one dose of RBX2660 (Groups A and C) were analyzed (Table 1).
  • RBX2660 significantly increased microbiome diversity compared to baseline (Table 2).
  • Patient baseline microbiomes were less diverse and more divergent from the “healthy” HMP microbiome. After treatment, patient microbiomes became more closely related to the HMP over time, with the largest shift observed after 7 days (Figures 3, 4, 5).
  • Specific taxonomic distributions were consistent with pres microbiome analyses of CDI patients. Taxonomic classes that diverged the most at baseline showed the largest longitudinal post-treatment change. (Figure 4).


Results show RBX2660 treatment shifts patient intestinal microbiomes closer to the healthy microbiome as defined by the Human Microbiome Project. In addition, RBX2660 significantly increases microbiome diversity compared to baseline.


  1. Dubberke ER et al. Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results of the PUNCH CD 2 Trial Infectious Diseases Week (ID Week) October 26-30, 2016, New Orleans, LA.